Overview

A Study of INCB050465 in Subjects With Relapsed or Refractory Marginal Zone Lymphoma (CITADEL-204)

Status:
Active, not recruiting
Trial end date:
2022-07-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and efficacy of two parsaclisib treatment regimens in participants diagnosed with relapsed or refractory marginal zone lymphoma (MZL) who are naive to or were previously treated with a Bruton's tyrosine kinase (BTK) inhibitor.
Phase:
Phase 2
Details
Lead Sponsor:
Incyte Corporation